Related Experiment Video

Updated: Mar 21, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.2K

New perspective on molecular markers as promising therapeutic targets in germ cell tumors

Paolo Chieffi1

  • 1Dipartimento di Psicologia, Seconda Università di Napoli, Caserta, Italy.

Intractable & Rare Diseases Research
|May 20, 2016
PubMed

Insights

Testicular germ cell tumors (TGCTs) are common in young men. Biomarkers like HMGA1 can help distinguish between TGCT subtypes, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Testicular germ cell tumors (TGCTs) are the most common solid tumors in men aged 20-40.
  • TGCTs are a leading cause of cancer death in this demographic.
  • TGCTs are classified into seminomas and non-seminomas (NSGCTs), with distinct clinical behaviors.

Purpose of the Study:

  • To review the characteristics of TGCTs, including their histological subtypes.
  • To highlight the differences in clinical presentation, treatment, and prognosis between seminomas and NSGCTs.
  • To discuss the role of biomarkers in differentiating TGCT subtypes and their potential as therapeutic targets.

Main Methods:

  • Review of existing literature on TGCTs.
  • Analysis of histological classifications and clinical features.
  • Examination of identified biomarkers and their diagnostic/therapeutic implications.

Main Results:

  • TGCTs originate from primordial germ cells (PGCs).
  • NSGCTs encompass embryonal carcinoma, teratoma, yolk sac tumor, and choriocarcinoma.
  • Biomarkers such as HMGA1, GPR30, Aurora-B, and estrogen receptor β aid in distinguishing histological subgroups.

Conclusions:

  • Seminomas and NSGCTs exhibit significant differences in clinical aspects and prognosis.
  • Identified biomarkers offer improved discrimination between TGCT subtypes.
  • These biomarkers represent promising avenues for targeted therapies in TGCT management.
Keywords:
Aurora BGPR30PATZ1; HMGATesticular germ cells tumorsseminomas

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K